Articles Tagged With: COVID-19
-
Small Fiber Neuropathy in Post-COVID Patients with Chronic Fatigue Syndrome
This study examines small fiber neuropathy (SFN) in post-COVID patients with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). While ME/CFS patients reported more SFN symptoms, objective testing showed limited diagnostic value beyond heat/cold detection differences.
-
Infectious Disease Updates
COVID Monoclonals Needed for PrEP; Oral Camostat Ineffective in COVID-19; Mpox: Lessons Learned from Rio
-
Cardiovascular Risk with mRNA COVID Vaccines
A large, nationwide population study in Sweden of the risk of adverse cardiovascular events after messenger ribonucleic acid (mRNA) COVID-19 vaccinations has shown that, except for rare cases of myopericarditis, severe cardiovascular events, such as myocardial infarction, heart failure, and stroke, are reduced, probably because of the prevention of COVID infection.
-
Effectiveness of Nirmatrelvir-Ritonavir in Hospitalized Patients with COVID-19
A study that compared nirmatrelvir-ritonavir, remdesivir, or a combination of both for hospitalized patients with COVID-19 found those who received nirmatrelvir-ritonavir monotherapy had lower mortality, reduced intensive care unit admission, and reduced need for mechanical ventilation.
-
Metformin Reduces SARS-CoV-2 Viral Load in Outpatients with COVID-19
A randomized, placebo-controlled clinical trial of outpatients with COVID-19 found that metformin reduced SARS-CoV-2 viral load 3.6-fold compared to placebo, while ivermectin and fluvoxamine showed no benefit.
-
Understanding Myocarditis, COVID-19 Infection, and COVID-19 Vaccines
Although myocarditis is rare, interest has increased in recent years because of the COVID-19 pandemic and COVID-19 vaccinations both being associated with its development. This review article will trace the history of myocarditis from the pre-COVID-19 era to the present day.
-
Does Semaglutide Protect Against Adverse Effects from COVID-19?
Semaglutide recipients who developed COVID-19 had significant protection against the occurrence of adverse outcomes, including death.
-
Myocarditis in a Post-COVID World
Myocarditis is a rare, typically self-limited inflammatory condition of the heart. Interest in myocarditis has increased in recent years because of the COVID-19 pandemic and COVID-19 vaccinations both being associated with its development. Paralleling this interest is an increase in misinformation about this condition, its frequency associated with both COVID-19 infection and vaccination, and potential linkage to sudden cardiac death. This review article will trace the history of myocarditis from the pre-COVID-19 era to the present day, with special attention being paid to how social media has driven a large portion of the discussion.
-
Does Semaglutide Protect Against Adverse Effects from COVID-19?
Semaglutide recipients who developed COVID-19 had significant protection against the occurrence of adverse outcomes, including death.
-
Metformin Reduces SARS-CoV-2 Viral Load in Outpatients with COVID-19
A randomized, placebo-controlled clinical trial of outpatients with COVID-19 found that metformin reduced SARS-CoV-2 viral load 3.6-fold compared to placebo, while ivermectin and fluvoxamine showed no benefit.